Perpetual Ltd Has $784,000 Position in Autolus Therapeutics PLC Sponsored ADR $AUTL

Perpetual Ltd lessened its holdings in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) by 42.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 481,081 shares of the company’s stock after selling 348,009 shares during the period. Perpetual Ltd owned approximately 0.18% of Autolus Therapeutics worth $784,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Armistice Capital LLC increased its position in Autolus Therapeutics by 19.6% in the 1st quarter. Armistice Capital LLC now owns 11,000,000 shares of the company’s stock worth $17,050,000 after buying an additional 1,800,000 shares during the period. Wellington Management Group LLP grew its stake in shares of Autolus Therapeutics by 6.9% in the first quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company’s stock worth $41,992,000 after acquiring an additional 1,746,020 shares during the last quarter. Bank of America Corp DE increased its position in Autolus Therapeutics by 2,891.7% during the second quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock worth $2,223,000 after acquiring an additional 942,540 shares during the period. TFG Asset Management GP Ltd increased its position in Autolus Therapeutics by 10.5% during the second quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock worth $21,660,000 after acquiring an additional 900,000 shares during the period. Finally, Atle Fund Management AB raised its stake in Autolus Therapeutics by 130.5% during the 2nd quarter. Atle Fund Management AB now owns 1,105,461 shares of the company’s stock valued at $2,520,000 after purchasing an additional 625,817 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.

Wall Street Analysts Forecast Growth

AUTL has been the topic of several research analyst reports. Wall Street Zen lowered shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th. William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a research report on Wednesday, September 24th. Needham & Company LLC restated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research note on Friday, December 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.33.

Autolus Therapeutics Trading Up 4.8%

NASDAQ:AUTL opened at $1.65 on Monday. The stock has a market capitalization of $437.81 million, a P/E ratio of -1.98 and a beta of 2.01. The firm has a 50 day moving average of $1.48 and a 200-day moving average of $1.80. Autolus Therapeutics PLC Sponsored ADR has a 1 year low of $1.11 and a 1 year high of $2.80.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). The company had revenue of $21.19 million during the quarter, compared to the consensus estimate of $21.08 million. Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%. As a group, analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.